Several preclinical studies using genetically engineered NF1 mouse models or established human tumor cell lines have demonstrated that mTOR overactivation underlies tumor proliferation in NF1, underpinning the therapeutic potential of rapamycin and its analogs [44,45,46]. The gene discussed is NF1; the disease is neoplasm.